Mesothelin (MSLN), a glycoprotein-based tumor antigen, is elevated in several malignancies and it is related to a poor prognosis, as it enhances tumor aggression, dissemination and chemotherapy resistance. MSLN plays a crucial role in epigenetic and signal pathway regulation and it can be an important biomarker. MSLN targeting is in particular, associated with CA125/MUC16, which offers the potential to improve lung, pancreatic, colon and ovarian cancer detection as well as therapeutic strategies. MSLNtargeted therapies have shown favorable results, such as CAR NK cells, 227Th conjugate and CAR-T cells, which target mesothelin. Significant advancements can be achieved with novel techniques, such as mesothelin-targeting BiTEs and simultaneous CAR-T cells. Immunotherapies targeting mesothelin have the potential to completely transform the way cancer is therapy in patients with limited options. To fully comprehend the mechanisms of MSLN, more investigation is required to explore its role in cancer for improved patient outcomes. The complex control, cellular functions and clinical significance of MSLN in the advancement of cancer are highlighted in this review.
间皮素（MSLN）是一种糖蛋白类肿瘤抗原，在多种恶性肿瘤中表达升高，因其能增强肿瘤侵袭性、扩散能力和化疗耐药性，与不良预后密切相关。MSLN在表观遗传调控和信号通路调节中发挥关键作用，可作为重要的生物标志物。MSLN靶向策略尤其与CA125/MUC16存在关联，这为改善肺癌、胰腺癌、结肠癌和卵巢癌的检测及治疗策略提供了潜力。针对间皮素的靶向疗法已显示出良好效果，例如靶向间皮素的CAR NK细胞、²²⁷Th偶联物和CAR-T细胞。通过新型技术如靶向间皮素的双特异性T细胞衔接器及同步CAR-T细胞疗法，可取得显著进展。针对间皮素的免疫疗法有望彻底改变治疗选择有限患者的癌症治疗模式。为全面理解MSLN的作用机制，需要进一步探索其在癌症发生发展中的功能，以改善患者预后。本综述重点阐述了MSLN在癌症进展中的复杂调控机制、细胞功能及临床意义。
Mesothelin as a Signal Pathways and Epigenetic Target in Cancer Therapy
肿瘤(癌症)患者之家